3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
38
Melanoma
15
Neoplasm Metastasis
12
Squamous Cell Carcinoma of Head and Neck
11
Lung Neoplasms
11
Skin Neoplasms
10
Neoplasms
9
Ovarian Neoplasms
8
Recurrence
7
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Urinary Bladder Neoplasms
6
Head and Neck Neoplasms
6
Carcinoma, Basal Cell
6
Breast Neoplasms
6
Adenocarcinoma
6
Uterine Cervical Neoplasms
5
Triple Negative Breast Neoplasms
5
Colonic Neoplasms
5
Carcinoma, Squamous Cell
5
Carcinoma, Merkel Cell
5
Carcinoma
5
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Mouth Neoplasms
4
Glioblastoma
4
Fallopian Tube Neoplasms
4
Stomach Neoplasms
3
Sarcoma
3
Mycosis Fungoides
3
Interventions
pembrolizumab
3
Paclitaxel
3
Doxorubicin
3
durvalumab
2
Standard of Care
2
Nivolumab
2
Ipilimumab
2
Ifosfamide
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
peginterferon alfa-2a
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
cemiplimab
×
1 year
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled